"For example, 73% of people with relapsing-remitting MS compared with 33% of people with secondary progressive MS experienced an absence of disease progression at the 5 year post-treatment assessment. - See more at: https://www.msif.org/news/2017/05/03/lo ... 71Nwf.dpuf"shadowfax wrote:Wow.....not sure I would want to spend $75,000CAD for a 33% chance of it working. I wonder if those stats could be broke down to include mylo vs non-mylo
As they say, this treatment is for RRMS. It is good to see that 33% of secondary progressive are doing well. I don't see anything about mylo vs non-mylo though.
- Similar Topics
- Last post